imatinib mesylate has been researched along with Diarrhea in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (40.74) | 29.6817 |
| 2010's | 12 (44.44) | 24.3611 |
| 2020's | 4 (14.81) | 2.80 |
| Authors | Studies |
|---|---|
| Doi, T; Honma, Y; Iwagami, S; Komatsu, Y; Kurokawa, Y; Naito, Y; Nishida, T; Sawaki, A; Takahashi, T | 1 |
| Chen, Y; Cheng, F; Cui, Z; Li, Q; Li, W; Zeng, F; Zhang, Y | 1 |
| Austin, G; Clark, RE; Davies, A; Foroni, L; Loaiza, S; Pirmohamed, M; Rodriguez-Vicente, AE | 1 |
| Li, J; Li, Y; Liu, X; Shen, L; Wu, X; Zhang, B; Zhang, X; Zhou, Y | 1 |
| Cubitt, C; Komrokji, RS; Lancet, JE; List, AF; Mirza, AS; Nardelli, L; Padron, E; Pinilla-Ibarz, J; Sweet, K | 1 |
| Fu, Y; Liang, J; Lin, L; Wei, X; Xu, W | 1 |
| Agrawal, S; Baruchel, A; Beverloo, BB; den Boer, ML; Dworzak, M; Kearns, PR; Lancaster, DL; Lehrnbecher, T; Manos, G; Mechinaud, F; Pieters, R; Reinhardt, D; Rizzari, C; Rosenberg, J; Strauss, L; van der Velden, VH; Zwaan, CM | 1 |
| Bhargava, S; Kumar, M; Malhotra, B; Malhotra, H; Rathore, OS; Sharma, P | 1 |
| Brümmendorf, TH; Cortes, JE; Dmoszynska, A; Duvillié, L; Gambacorti-Passerini, C; Gogat Marchant, K; Kantarjian, HM; Khattry, N; Lipton, JH; Pavlov, D; Rossiev, V; Wong, RS | 1 |
| Bardy-Bouxin, N; Brümmendorf, TH; Cortes, JE; Gambacorti-Passerini, C; Kantarjian, HM; Khoury, HJ; Kim, DW; Leip, E; Matczak, E; Shapiro, M; Turkina, AG; Turnbull, K | 1 |
| Akker, M; Cevik, G; Demir, AM; Maden, M; Merev, E; Pamuk, GE; Umit, EG; Uyanik, MS; Uyanik, V | 1 |
| Druker, B; Gathmann, I; Guilhot, F; Larson, RA; O'Brien, SG; So, C; Waltzman, R | 1 |
| Akard, L; Albitar, M; Burke, JM; Cortes, JE; Giles, FJ; Goldberg, SL; Kantarjian, HM; Kerr, R; McDougall, K; Powell, BL; Radich, J; Saleh, M; Salvado, A; Wetzler, M | 1 |
| Buonerba, C; Ceribelli, A; Conti, S; Damiano, V; De Placido, S; Di Lorenzo, G; Evoli, A; Federico, P; Lalle, M; Marino, M; Matano, E; Merola, G; Milella, M; Palmieri, G; Petillo, L; Sioletic, S | 1 |
| de Leon, F; McBain, D; Petrlich, L; Pope, J; Seney, S; Summers, K; Vanderhoek, L; Watson, S | 1 |
| Coan, A; Desjardins, A; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Lipp, ES; McLendon, R; Peters, KB; Reardon, DA; Rich, JN; Sathornsumetee, S; Vredenburgh, JJ | 1 |
| Cervantes, F; le Coutre, P; Porkka, K; Saglio, G; Steegmann, JL | 1 |
| Berstad, A; Eklund, KK; Kovanen, PT; Lappalainen, J; Lin, AH; Mäyränpää, MI; Vaali, K | 1 |
| Cáceres, W; Corujo, Y | 1 |
| Deininger, MW; Druker, BJ; Ford, JM; O'Brien, SG | 1 |
| Bubley, GJ; Chatis, P; Crosby, K; Dezube, BJ; Egorin, MJ; Koon, HB; Masiello, D; Miller, TE; Pantanowitz, L; Proper, J; Smith, B; Tahan, SR; Weeden, W | 1 |
| Chung, JH; Ha, E; Jung, KH; Kim, BS; Park, HJ; Park, YH; Yim, SV; Yoon, SH | 1 |
| Krcmová, L; Melichar, B; Opletalová, V; Solich, P; Solichová, D; Urbánek, L | 1 |
| Cortes, J; Estrov, Z; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Ladie, N; Murgo, A; O'Brien, S; Quintás-Cardama, A; Verstovsek, S | 1 |
| Arthur, C; Branford, S; Filshie, R; Hughes, T; Koelmeyer, R; Lynch, K; Milner, A; Moreton, S; Schwarer, A; Taylor, K | 1 |
| Cortes, J; Daley, GQ; Ferrajoli, A; Jabbour, E; Kantarjian, H; Koller, C; O'Brien, S; Statkevich, P; Verstovsek, S; Zhu, Y | 1 |
| Benson, K; Chen, G; Cohen, MH; Duan, J; Gobburu, J; Johnson, JR; Kim, SK; Leighton, J; Pazdur, R; Rahman, A; Rothmann, M; Staten, AM; U, KM; Williams, G; Wood, R | 1 |
3 review(s) available for imatinib mesylate and Diarrhea
| Article | Year |
|---|---|
Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia.
Topics: Benzamides; Dasatinib; Diarrhea; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Thiazoles; Thrombocytopenia; Time Factors | 2012 |
Signal transduction inhibitors (STI571): molecularly targeted therapy.
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Diarrhea; Edema; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nausea; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction | 2002 |
Practical management of patients with chronic myeloid leukemia receiving imatinib.
Topics: Antineoplastic Agents; Arthralgia; Benzamides; Bone Marrow; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Drug Interactions; Edema; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Cell Growth Factors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Liver; Muscle Cramp; Nausea; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Vomiting | 2003 |
16 trial(s) available for imatinib mesylate and Diarrhea
| Article | Year |
|---|---|
Pimitespib in patients with advanced gastrointestinal stromal tumor (CHAPTER-GIST-301): a randomized, double-blind, placebo-controlled phase III trial.
Topics: Antineoplastic Agents; Diarrhea; Double-Blind Method; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Pyrroles | 2022 |
Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dasatinib; Diarrhea; Female; Gene Frequency; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Minisatellite Repeats; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Serotonin Plasma Membrane Transport Proteins; Young Adult | 2020 |
A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.
Topics: Administration, Oral; Adult; Aged; Anemia; Antineoplastic Agents; Dasatinib; Diarrhea; DNA Copy Number Variations; Drug Administration Schedule; Fatigue; Female; Gastrointestinal Stromal Tumors; Genotype; High-Throughput Nucleotide Sequencing; Humans; Imatinib Mesylate; Male; Middle Aged; Mutation; Neutropenia; Progression-Free Survival; Prospective Studies; Protein Kinase Inhibitors; Proteinuria; Sunitinib | 2020 |
A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Diarrhea; Drug Resistance, Neoplasm; Edema; Female; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Treatment Outcome | 2017 |
Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Topics: Adolescent; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Dasatinib; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Headache; Humans; Imatinib Mesylate; Infant; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Nausea; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Sample Size; Therapies, Investigational; Thiazoles; Treatment Outcome; Vomiting; Young Adult | 2013 |
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.
Topics: Alanine Transaminase; Aniline Compounds; Antineoplastic Agents; Aspartate Aminotransferases; Benzamides; Diarrhea; Female; Fever; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Muscle Cramp; Myalgia; Nitriles; Pain; Piperazines; Pyrimidines; Quinolines; Vomiting | 2014 |
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Benzamides; Blast Crisis; Diarrhea; Drug Resistance, Neoplasm; Female; Fever; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Nitriles; Piperazines; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Survival Analysis; Treatment Outcome | 2015 |
High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cross-Over Studies; Cytarabine; Diarrhea; Drug Administration Schedule; Edema; Humans; Imatinib Mesylate; Interferon-alpha; Kaplan-Meier Estimate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Muscle Cramp; Nausea; Piperazines; Pyrimidines; Remission Induction; Survival Rate; Treatment Outcome | 2009 |
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Nausea; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Time Factors; Treatment Outcome; Young Adult | 2009 |
Imatinib mesylate in thymic epithelial malignancies.
Topics: Adult; Benzamides; Diarrhea; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Middle Aged; Migraine Disorders; Mutation; Neoplasms, Glandular and Epithelial; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Thymus Neoplasms; Treatment Outcome | 2012 |
Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.
Topics: Adult; Aged; Alopecia; Anemia; Benzamides; Diarrhea; Double-Blind Method; Early Termination of Clinical Trials; Edema; Female; Humans; Imatinib Mesylate; Male; Middle Aged; Nausea; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Scleroderma, Diffuse; Surveys and Questionnaires; Treatment Outcome | 2011 |
Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Benzamides; Brain Neoplasms; Cohort Studies; Dacarbazine; Diarrhea; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Hydroxyurea; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Oligodendroglioma; Piperazines; Pyrimidines; Temozolomide; Thrombocytopenia; Treatment Outcome | 2012 |
Imatinib-induced regression of AIDS-related Kaposi's sarcoma.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Antineoplastic Agents; Benzamides; Biopsy; Diarrhea; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Pilot Projects; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Remission Induction; Sarcoma, Kaposi; Signal Transduction; Skin Neoplasms; Vascular Endothelial Growth Factor A | 2005 |
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Topics: Adult; Aged; Anemia; Antineoplastic Agents, Phytogenic; Benzamides; Blast Crisis; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Harringtonines; Homoharringtonine; Humans; Imatinib Mesylate; Injections, Intravenous; Injections, Subcutaneous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Nausea; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Failure; Treatment Outcome | 2007 |
Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diarrhea; Follow-Up Studies; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neutropenia; Patient Dropouts; Piperazines; Prospective Studies; Pyrimidines; Time Factors; Transcription, Genetic; Treatment Outcome | 2007 |
Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Piperidines; Pyridines; Pyrimidines; Treatment Failure; Treatment Outcome; Vomiting | 2007 |
8 other study(ies) available for imatinib mesylate and Diarrhea
| Article | Year |
|---|---|
Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic-phase chronic myeloid leukemia.
Topics: Antineoplastic Agents; Benzamides; China; Diarrhea; Drug Monitoring; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Piperazines; Pyrimidines | 2022 |
Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Stromal Tumors; Humans; Hypertension; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Sorafenib; Sunitinib | 2018 |
Correlation of plasma trough levels of imatinib with molecular response in patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Diarrhea; Fatigue; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Muscle Cramp; Nausea; Outcome Assessment, Health Care; Piperazines; Pyrimidines; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Young Adult | 2014 |
The impact of new generic formulations of imatinib mesylate on general quality of life in chronic phase chronic myeloid leukaemia patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Anxiety; Depression; Diarrhea; Drugs, Generic; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Linear Models; Maintenance Chemotherapy; Male; Middle Aged; Multivariate Analysis; Protein Kinase Inhibitors; Quality of Life; Time Factors | 2017 |
Imatinib mesylate alleviates diarrhea in a mouse model of intestinal allergy.
Topics: Allergens; Animals; Benzamides; Diarrhea; Disease Models, Animal; Female; Food Hypersensitivity; Imatinib Mesylate; Intestines; Mast Cells; Mice; Ovalbumin; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction | 2012 |
BNP as a marker of the heart failure in the treatment of imatinib mesylate.
Topics: Adult; Aged; Alleles; Base Sequence; Benzamides; Biomarkers, Tumor; Diarrhea; DNA Mutational Analysis; Edema; Exanthema; Female; Gastrointestinal Stromal Tumors; Gene Frequency; Genotype; Heart Failure; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Natriuretic Peptide, Brain; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome | 2006 |
Development and validation of a liquid chromatography method for the simultaneous determination of alpha-tocopherol, retinol and retinyl esters in human serum using a monolithic column for the monitoring of anticancer therapy side effects.
Topics: Absorption; alpha-Tocopherol; Antineoplastic Agents; Benzamides; Calibration; Chromatography; Chromatography, High Pressure Liquid; Diarrhea; Drug Monitoring; Esters; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Reproducibility of Results; Time Factors; Vitamin A | 2006 |
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Benzamides; Capsules; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Diarrhea; Drug Approval; Exanthema; Headache; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Nausea; Piperazines; Pyrimidines; Treatment Outcome; United States; United States Food and Drug Administration; Vomiting | 2002 |